<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02603666</url>
  </required_header>
  <id_info>
    <org_study_id>2010/1957/31/3</org_study_id>
    <nct_id>NCT02603666</nct_id>
  </id_info>
  <brief_title>Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects</brief_title>
  <official_title>Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to find CF patients at risk for cystic fibrosis related liver disease
      (CFLD). Comparison of ultrasound by two modalities and biochemical markers with histological
      evaluation of liver biopsy if present.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 209 CF patients attending Stockholm Cystic Fibrosis Center (January 2010). All up
      till 15 years of age are screened for liver disease annually by ultrasound (US) and also by
      biochemical markers. Ultrasound is performed every third year over 15 years of age in
      patients without CFLD, while all of them with diagnosed CFLD are continued to be investigated
      annually. Biochemical markers are controlled at least once every year in all CF patients.
      Elastography of the liver will be planned together with the investigations of the annual
      follow up, in an optimal clinical status. If either US or elastography of the liver indicates
      liver disease or progress of the already existing pathological changes, a liver biopsy will
      be performed according to routine procedure at Stockholm CF Centre. Also, historical data of
      liver biopsies and biochemical investigations will be considered in the study.

      Elastography of the liver will be performed by Fibroscan device, with transducers for
      children and adults, respectively.

      Clinical importance Liver US investigations in CF patients have important implications but
      are difficult to standardize in a routine clinical setting. Elastography may have an
      advantage in the evaluation of early fibrosis with clinical importance in pursuing
      diagnostics and intensifying treatment. A significant group (up to 25 %) of CF patients may
      be helped by this novel method. Including histological data, accuracy of elastography in CF
      patients may be improved. Further details of the importance of fatty acid status in CF may be
      elucidated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elastographic Value in kPa Measured by Fibroscan</measure>
    <time_frame>Within 28 days in connection with their annual evaluation at a single point of time</time_frame>
    <description>Elastographic values given in kPa by Fibroscan. All patients undergo elastographic measurement of the liver and ultrasound of the liver. The grade of fibrosis is to be established by setting the cut-off for cystic fibrosis patients.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Elastography</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fibroscan elastography device for evaluation of liver disease in CF patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fibroscan</intervention_name>
    <description>Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.</description>
    <arm_group_label>Elastography</arm_group_label>
    <other_name>Elastography</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Verified cystic fibrosis

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ferenc Karpati, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stockholm CF Center, Karolinska University Hospital</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <results_first_submitted>September 6, 2016</results_first_submitted>
  <results_first_submitted_qc>November 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2016</results_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Ferenc Karpati</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>elastography</keyword>
  <keyword>liver biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Outpatient department, between 04/Feb/2012 and 04/Apr/2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Elastography</title>
          <description>Fibroscan elastography device for evaluation of liver disease in CF patients.
Fibroscan: Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Elastography</title>
          <description>Fibroscan elastography device for evaluation of liver disease in CF patients.
Fibroscan: Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Stockholm Cystic Fibrosis Center, Sweden Prospective inclusion</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Elastographic Value in kPa Measured by Fibroscan</title>
        <description>Elastographic values given in kPa by Fibroscan. All patients undergo elastographic measurement of the liver and ultrasound of the liver. The grade of fibrosis is to be established by setting the cut-off for cystic fibrosis patients.</description>
        <time_frame>Within 28 days in connection with their annual evaluation at a single point of time</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Elastography</title>
            <description>Fibroscan elastography device for evaluation of liver disease in CF patients.
Fibroscan: Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.</description>
          </group>
        </group_list>
        <measure>
          <title>Elastographic Value in kPa Measured by Fibroscan</title>
          <description>Elastographic values given in kPa by Fibroscan. All patients undergo elastographic measurement of the liver and ultrasound of the liver. The grade of fibrosis is to be established by setting the cut-off for cystic fibrosis patients.</description>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="4.3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Elastography</title>
          <description>Fibroscan elastography device for evaluation of liver disease in CF patients.
Fibroscan: Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ferenc Karpati M.D., Ph.D., Senior Consultant</name_or_title>
      <organization>Karolinska University Hospital, Huddinge, 141 86 Stockholm</organization>
      <phone>+46858580000 ext 81656</phone>
      <email>ferenc.karpati@karolinska.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

